

Revision date: 11-Apr-2012 Version: 2.0 Page 1 of 5

IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Pfizer Ltd

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

Trade Name: KITNOS Chemical Family: Mixture

Material Name: Etofamide Oral Suspension

Intended Use: Pharmaceutical product used as Amebicide

2. HAZARDS IDENTIFICATION

Appearance: Oral Suspension

Statement of Hazard: Non-hazardous in accordance with international standards for workplace safety.

Additional Hazard Information:

Short Term: Not acutely toxic (based on animal data) . Accidental ingestion may cause effects similar to

those seen in clinical use.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include headache, diarrhea, nausea,

and flatulence. Adverse clinical reactions include the development of hypersensitivity and/or

irritation leading to rashes, itching, and burning.

EU Indication of danger: Not classified

Australian Hazard Classification

(NOHSC):

Non-Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which

require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your

workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Etofamide	25287-60-9	246-790-2	Not Listed	200 mg ***
Non-hazardous ingredients	NOT APPLICABLE	Not Listed	Not Listed	*

D70000

Material Name: Etofamide Oral Suspension Page 2 of 5
Revision date: 11-Apr-2012 Version: 2.0

Additional Information: * Proprietary

*** per tablet/capsule/lozenge/suppository

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Emits toxic fumes of carbon monoxide, oxides of nitrogen and hydrogen chloride.

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Material Name: Etofamide Oral Suspension Page 3 of 5

Revision date: 11-Apr-2012 Version: 2.0

7. HANDLING AND STORAGE

General Handling: Avoid contact with skin and clothing. Avoid breathing vapor or mist. When handling, use

appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the

atmosphere should be controlled with dust collectors, HEPA filtration systems or other

equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Etofamide

Pfizer Occupational Exposure OEB 1 (control exposure to the range of >1000ug/m³ to < 3000ug/m³)

Band (OEB):

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Impervious gloves are recommended if skin contact with drug product is possible and for bulk

processing operations.

Eyes: Wear safety glasses or goggles if eye contact is possible.

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear

an appropriate respirator with a protection factor sufficient to control exposures to the bottom of

the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Suspension Color: No data available.

Odor: Banana Molecular Formula: Mixture

Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the active ingredient.

D700000

Material Name: Etofamide Oral Suspension Page 4 of 5 Version: 2.0

Revision date: 11-Apr-2012

11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Etofamide

Oral LD 50 > 5000 mg/kg Rat

Sub-tenon injection (eye) LD 50 2000 mg/kg

Mouse Oral LD 50 > 5000 mg/kg

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable **Acute Toxicity Comments:**

at the highest dose used in the test.

None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Carcinogen Status:

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Not classified **EU** Indication of danger:

OSHA Label:

Non-hazardous in accordance with international standards for workplace safety.

Canada - WHMIS: Classifications

Material Name: Etofamide Oral Suspension Page 5 of 5
Revision date: 11-Apr-2012 Version: 2.0

P 1

15. REGULATORY INFORMATION

WHMIS hazard class:

None required

This product has been classified in accordance with the hazard criteria of the CPR and the MSDS contains all of the information required by the CPR.

Etofamide

EU EINECS/ELINCS List 246-790-2

16. OTHER INFORMATION

Data Sources: Publicly available toxicity information.

Reasons for Revision: Updated Section 7 - Handling and Storage. Updated Section 8 - Exposure Controls / Personal

Protection. Updated Section 10 - Stability and Reactivity. Updated Section 2 - Hazard

Identification.

Prepared by: Product Stewardship Hazard Communication

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
